Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5760012

Title:Methods and compounds for curing diseases caused by mutations
Inventors:Kmiec, Eric B.; Malvern, PA, USA
Cole-Strauss, Allyson; Philadelphia, PA, USA
Yoon, Kyonggeun; Berwyn, PA, USA
Summary:Described herein are chimeric nucleic acid repair vectors, methods and uses thereof. The invention relates to a nucleic acid characterized by not more than one 3' end and one 5' end which comprise a segment of unpaired bases configured in such a manner that the unpaired bases separate the nucleic acid into a first strand and a second strand, such that first and second strands comprise a first region and a second region, respectively, with each region having at least 15 nucleotides. Further disclosed are properties by which each nucleotide of the first region is Watson-Crick paired to a nucleotide of the second region such that the first region comprises at least 8 ribonucleotides having other than a 2'-hydroxyl moiety, which are Watson-Crick paired to 2'-deoxynucleotides such that the ribonucleotides form at least one ribonucleotide segment of at least 3 ribonucleotides by which the sequence of the first or the second region is the sequence of a fragment of a wild-type allele of a human gene. Therapeutic applications are included for the treatment of diseases such as sickle cell anemia, beta-thalassemia, Gaucher disease, hypercholesterolemia, emphysema and hemophilia.
Abstract:The invention concerns the use of duplex oligonucleotides having both 2'-deoxyribonucleotides and ribonucleotides, wherein there is base pairing between the two types of nucleotides. The sequence of the oligonucleotide is selected so that the 3' and 5' most regions of the oligonucleotide are homologous with (identical to) the sequence of a preselected target gene of a cell. The two regions of homology embrace a region that is heterologous with the target sequence. The introduction of the oligonucleotide into the nucleus of the cell causes the alteration of the target gene such that the sequence of the altered target gene is the sequence of the heterologous region. Consequently, the oligonucleotides of the invention are termed Chimeric Repair Vectors (CRV). In one embodiment of the invention the target gene is a globin gene and the target cell is a hematopoietic stem cell. This embodiment can be used to correct certain hemoglobinopathies such as Sickle Cell Disease, .beta.-thalassemia, and also Gaucher Disease. The rate of correction of the globin gene is high enough so that no selection of the treated hematopoietic stem cells is required to obtain a therapeutically significant effect. In one embodiment the ribose moieties of the nucleotides of the CRV contain methylated 2'-oxygens.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5760012
Application Number:US1996000640517
Date Filed:01/05/1996
Date Published:02/06/1998
Assignee:Thomas Jefferson University, Philadelphia, PA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/10/2020